Peritoneum cancer
MONDO:0002087A malignant neoplasm involving the peritoneum
Also known as: cancer of peritoneum, cancer of the peritoneum, malignant neoplasm of peritoneum, malignant peritoneal neoplasm, malignant peritoneum neoplasm, peritoneal cancer, peritoneal cavity cancer, peritoneum cancer
3216 clinical trials for this condition and its sub-types, 67 tagged with Peritoneum cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Peritoneum cancer
-
Peritoneal carcinoma 16 trials · 389 incl. sub-types
3 sub-types
- Primary peritoneal carcinoma 351 trials · 361 incl. sub-types Sub-types →
- Peritoneal serous adenocarcinoma 2 trials · 39 incl. sub-types Sub-types →
- Pseudomyxoma peritonei 17 trials
-
Peritoneal carcinomatosis 90 trials · 100 incl. sub-types
1 sub-type
- Pseudomyxoma peritonei 17 trials
-
Malignant peritoneal mesothelioma 13 trials
-
Malignant peritoneal germ cell tumor 0 trials
-
Round ligament malignant neoplasm 0 trials
Most studied deeper sub-types
-
Could a daily aspirin boost ovarian cancer treatment?
Disease control PausedThis early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goa…
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New triple therapy aims to shrink abdominal tumors in colorectal cancer
Disease control OngoingThis phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for Stomach-Lining cancer: direct chemo attack
Disease control OngoingThis early-phase trial tests whether giving two standard chemotherapy drugs (5FU and oxaliplatin) directly into the abdominal cavity is safe for people with colorectal cancer that has spread only to the peritoneal lining. About 24 adults will receive the drugs through a catheter …
Phase 1 • Sponsor: Arjun Mittra • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Radioactive antibody targets rare childhood cancer
Disease control OngoingThis phase 2 trial tests a combination treatment for desmoplastic small round cell tumor (DSRCT), a rare cancer that often spreads in the abdomen. Participants receive a single dose of a radioactive antibody called 131I-omburtamab directly into the abdomen, followed by targeted r…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktail aims to fight stomach cancer in the abdomen
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingThis Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to stall ovarian Cancer's return
Disease control OngoingThis phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …
Phase 2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control OngoingThis study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. While som…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Phase 3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could chemo around surgery beat cancer spread in the belly?
Disease control OngoingThis study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…
Phase 2/3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental CAR T-Cell therapy targets Hard-to-Treat ovarian cancer
Disease control OngoingThis early-phase study tests a new treatment for women with recurrent epithelial ovarian cancer. The therapy uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called B7-H3. The main goal is to check safety and find the best dose, w…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can acupuncture with electricity help cancer patients recover from aggressive treatment?
Symptom relief OngoingThis study looks at whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help manage pain, nausea, diarrhea, and insomnia in people who have had cytoreductive surgery and heated chemotherapy for cancer. The trial will enroll 20 patients to see if the…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
What makes ovarian cancer survivors thrive? scientists investigate diet, mood, and support
Knowledge-focused OngoingThis study looks at women who have lived at least seven years after an ovarian cancer diagnosis. Researchers want to learn how diet, exercise, emotions, and social support may be linked to long-term survival. Participants fill out questionnaires and take part in interviews about …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to ease life after ovarian and endometrial cancer
Knowledge-focused OngoingThis study tests a personalized post-cancer care plan for women who have finished treatment for ovarian or endometrial cancer. About 99 participants will receive a day of support care and a tailored plan to address their needs. The goal is to see if this approach improves their l…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can a simple nudge get ovarian cancer patients to the right specialist faster?
Knowledge-focused OngoingThis study tests whether a gentle reminder to doctors can increase referrals to gynecologic oncology for women with suspicious ovarian masses. Researchers will send a message to ordering providers within 48 hours of imaging results, encouraging them to refer patients. The study i…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:04 UTC